Multilayer beads for pharmaceutical use
Multilayer beads for pharmaceutical use having a drug-in-polymer layer are disclosed. The disclosed multilayer beads for pharmaceutical use have (a) a core particle; (b) an optional barrier layer coated on the surface of the core particle; (c) a drug-in-polymer layer coated on the surface of the core or the barrier layer, (d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and (e) optionally one or more outer layers external to the drug-in-polymer layer or the sealant layer. The drug-in-polymer layer consists essentially of (i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or a mixture thereof. The drug-in-polymer layer may be solid dispersion of the drug in the polymer. Pharmaceutical compositions comprising a plurality of multilayer beads and a pharmaceutically acceptable excipient and methods of treating a gastrointestinal disorder are also disclosed.
1. A multilayer bead comprising:
(a) a core particle, wherein the core particle is drug-free;
(b) an optional barrier layer coated on the surface of the core particle;
(c) a drug-in-polymer layer coated on the surface of the core particle or, when present, the barrier layer, wherein the drug-in-polymer layer comprises:
(i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and
(ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof;
(d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and
(e) optionally one or more outer layers external to the drug-in-polymer layer or, when present, the sealant layer.
2. The multilayer bead of claim 1 , wherein the core particle is selected from the group consisting of microcrystalline cellulose particles, silica particles, and sugar particles.
3. The multilayer bead of claim 1 , wherein the drug is selected from the group consisting of:
(−)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid, (lubiprostone);
(−)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid, (cobiprostone);
(+)-isopropyl (Z)-7-[(IR,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoate, (isopropyl unoprostone);
(Z)-7-[(IR,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid;
(−)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid; and
(E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid.
4. The multilayer bead of claim 1 , wherein the drug is present in an amount from about 0.01 μg to about 0.2 μg.
5. The multilayer bead of claim 1 , wherein the drug and the polymer are present in a relative amount from about 1 part drug per about 0.2 part polymer to about 1 part drug per about 10,000 parts polymer.
6. The multilayer bead of claim 1 , wherein the barrier layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.
7. The multilayer bead of claim 1 , wherein the sealant layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.
8. The multilayer bead of claim 1 , wherein at least one outer layer is present and comprises a polymer that insoluble at a pH ranging from 5 to 8 and is soluble at pH ranging from 1 to 4, or a polymer that is insoluble at a pH ranging from 6 to 8 and is soluble at pH ranging from 1 to 5.
9. The multilayer bead of claim 1 , wherein at least one outer layer is present and comprises a methacrylate-based polymer.
10. The multilayer bead of claim 1 , wherein the barrier layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof, and the sealant layer is present and comprises a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, and a mixture thereof.
11. The multilayer bead of claim 10 , wherein:
(a) the core particle comprises microcrystalline cellulose;
(b) the barrier layer comprises a vinylpyrrolidone-vinyl acetate copolymer;
(c) the drug-in-polymer layer comprises a therapeutically effective amount of lubiprostone or a pharmaceutically acceptable salt or isomer thereof and a vinylpyrrolidone-vinyl acetate copolymer; and
(d) the sealant layer comprises a vinylpyrrolidone-vinyl acetate copolymer.
12. The multilayer bead of claim 1 , wherein:
(a) the core particle comprises microcrystalline cellulose;
(b) the barrier layer is present and comprises a vinylpyrrolidone-vinyl acetate copolymer;
(c) the drug-in-polymer layer comprises a therapeutically effective amount of lubiprostone or a pharmaceutically acceptable salt or isomer thereof and a vinylpyrrolidone-vinyl acetate copolymer;
(d) the sealant layer is present and comprises a vinylpyrrolidone-vinyl acetate copolymer; and
(e) one outer layer is present and comprises a copolymer comprising butyl methacrylate.
13. The multilayer bead of claim 12 , wherein the barrier layer, drug-in-polymer layer, sealant layer, outer layer, or any combination thereof comprises one or more pharmaceutically acceptable excipients.
14. The multilayer bead of claim 13 , wherein the one or more pharmaceutically acceptable excipients is talc, polyethylene glycol, or a combination thereof.
15. The multilayer bead of claim 12 , wherein lubiprostone is present in an amount from about 0.01 μg to about 0.2 μg.
16. The multilayer bead of claim 15 , wherein the amount of lubiprostone is from about 0.04 μg to about 0.08 μg.
17. The multilayer bead of claim 12 , wherein lubiprostone and the vinylpyrrolidone-vinyl acetate copolymer are present in a relative amount from about 1 part lubiprostone per about 0.2 part vinylpyrrolidone-vinyl acetate copolymer to about 1 part lubiprostone per about 10,000 parts vinylpyrrolidone-vinyl acetate copolymer.
18. The multilayer bead of claim 17 , wherein the relative amount of lubiprostone and the vinylpyrrolidone-vinyl acetate copolymer is from about 1 part lubiprostone per about 200 parts vinylpyrrolidone-vinyl acetate copolymer to about 1 part lubiprostone per about 1,000 parts vinylpyrrolidone-vinyl acetate copolymer.
19. A pharmaceutical composition comprising a plurality of multilayer beads according to claim 1 and at least one pharmaceutically acceptable excipient.
20. The pharmaceutical composition of claim 19 , wherein the plurality of multilayer beads is contained in a capsule, a sachet, or a pouch.
21. The pharmaceutical composition of claim 20 , wherein the capsule is a sprinkle capsule.
22. The pharmaceutical composition of claim 19 , wherein the plurality of multilayer beads provides from about 1 pg to about 75 pg of the drug.
23. The pharmaceutical composition of claim 22 , wherein the drug is lubiprostone.
24. A method for treating a gastrointestinal disorder, the method comprising orally administering to a patient in need thereof a therapeutically effective amount of the multilayer beads in the pharmaceutical composition of claim 19 .
25. The method of claim 24 , further comprising sprinkling the multilayer beads in pharmaceutical composition into water or onto a soft food substance prior to orally administering to the patient.
26. The method of claim 24 , wherein the gastrointestinal disorder is selected from the group consisting of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation.
27. The method of claim 24 , wherein the patient is a pediatric patient or a geriatric patient.